Common Contracts
25 similar Common Stock Sales Agreement contracts by Editas Medicine, Inc., Jounce Therapeutics, Inc., Macrogenics Inc, others
MacroGenics, Inc. $100,000,000 Common Stock SALES AGREEMENTCommon Stock Sales Agreement • March 15th, 2023 • Macrogenics Inc • Pharmaceutical preparations • New York
MacroGenics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
2 - contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such registration statement pursuant to Rule 430B or 462(b) of the Securities Act, or...Common Stock Sales Agreement • November 8th, 2022 • Anaptysbio, Inc • Pharmaceutical preparations • New York
Avidity Biosciences, Inc. COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • November 8th, 2022 • Avidity Biosciences, Inc. • Pharmaceutical preparations • New York
Avidity Biosciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
EOS ENERGY ENTERPRISES, INC. $100,000,000 COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • August 5th, 2022 • Eos Energy Enterprises, Inc. • Miscellaneous electrical machinery, equipment & supplies • New York
Eos Energy Enterprises, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
APPHARVEST, INC. COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • August 3rd, 2022 • AppHarvest, Inc. • Agricultural production-crops • New York
AppHarvest, Inc., a Delaware public benefit corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
Edgewise Therapeutics, Inc. Common stock SALES AGREEMENTCommon Stock Sales Agreement • April 1st, 2022 • Edgewise Therapeutics, Inc. • Pharmaceutical preparations • New York
Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
JOUNCE THERAPEUTICS, INC. COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • November 4th, 2021 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Jounce Therapeutics, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
Annexon, Inc. COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • August 16th, 2021 • Annexon, Inc. • Pharmaceutical preparations • New York
100,000,000 COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • November 4th, 2020 • Macrogenics Inc • Pharmaceutical preparations • New York
MacroGenics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
TWIST BIOSCIENCE CORPORATION COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • December 18th, 2019 • Twist Bioscience Corp • Biological products, (no disgnostic substances) • New York
Twist Bioscience Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
JOUNCE THERAPEUTICS, INC. COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • December 17th, 2019 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Jounce Therapeutics, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
ALLOGENE THERAPEUTICS, INC. $250,000,000 COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • November 5th, 2019 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
INVITAE CORPORATION $75,000,000 COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • February 28th, 2019 • Invitae Corp • Services-medical laboratories • New York
Invitae Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
TONIX PHARMACEUTICALS HOLDING CORP. $9,500,000 COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • May 1st, 2018 • Tonix Pharmaceuticals Holding Corp. • Pharmaceutical preparations • New York
Tonix Pharmaceuticals Holding Corp. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • March 12th, 2018 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
Editas Medicine, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
ACHAOGEN, INC. $50,000,000 COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • February 27th, 2018 • Achaogen Inc • Pharmaceutical preparations • New York
Achaogen, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
VIVEVE MEDICAL, INC. $25,000,000 COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • November 8th, 2017 • Viveve Medical, Inc. • Electromedical & electrotherapeutic apparatus • New York
CHIMERIX, INC. $75,000,000 COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • November 8th, 2017 • Chimerix Inc • Pharmaceutical preparations • New York
COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • September 20th, 2017 • Corvus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Corvus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
Fluidigm Corporation $30.0 MILLION COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • August 3rd, 2017 • Fluidigm Corp • Laboratory analytical instruments • New York
Fluidigm Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
TONIX PHARMACEUTICALS HOLDING CORP. $9,000,000 COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • August 1st, 2017 • Tonix Pharmaceuticals Holding Corp. • Pharmaceutical preparations • New York
Tonix Pharmaceuticals Holding Corp. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • March 3rd, 2017 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
Editas Medicine, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
25,000,000 COMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • September 14th, 2016 • Opgen Inc • Services-medical laboratories • New York
ADURO BIOTECH, INC. $100,000,000 cOMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • May 2nd, 2016 • Aduro Biotech, Inc. • Pharmaceutical preparations • New York
PROTEON THERAPEUTICS, INC. $40,000,000 cOMMON STOCK SALES AGREEMENTCommon Stock Sales Agreement • November 12th, 2015 • Proteon Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Proteon Therapeutics, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
